For inquiries, please contact email@example.com
We are hiring. Apply by 8th of November 2020.
GenomEra SARS-CoV-2 Assay Kit is now CE IVD approved and development for four-in-one test (FluA, FluB, RSV, SARS-CoV-2) is on-going
GenomEra SARS-CoV-2 Assay Kit is now CE IVD approved and available. Please contact your local distributor or us for more information.
In addition, we are developing a four-in-one test for detecting influenza A, influenza B, RSV and SARS-CoV-2. Targeted release is before winter Flu season 2020-2021.
We warmly welcome all new investors!
Finnish regulatory authority Fimea has granted special approval for Abacus to supply the GenomEra RUO SARS-CoV-2 test to Finnish markets.
Press release in Finnish
Our team has been working hard on past weeks and today we shipped first GenomEra SARS-CoV-2 test kits for our customers.
Press-release in Finnish: https://bit.ly/2UvaMC2
Abacus is now on Twitter! We will tweet the latest news and more relaxed stories frequently. Some big news coming next week – stay tuned! https://twitter.com/AbacusCDX #AbacusCDX
Recent publication: GenomEra C. difficile test demonstrates increased reliability for standalone molecular diagnostics
While covid19 is spreading, there are still other worries to deal with. Standalone PCR testing for C. difficile diagnostics is often criticized for overdiagnosis of CDI. In a recent publication (doi:10.1128/JCM.01872-19) GenomEra routine samples were retested with two different toxin immunoassays and discrepant results were confirmed with culture or GeneXpert. Results shows perfect 100% PPV and excellent 99.7% NPV for GenomEra. Study reports insufficient sensitivities of 81.6% and 71.7% for two different toxin immunoassay from ArcDia and TechLab, respectively.
We are proud to announce our new distributor:
-NexGen Molecular Supplies, South Africa.